- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
New P1/2 trial, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2016 P1/2, N=30, Not yet recruiting,
- |||||||||| buparlisib (AN2025) / Adlai Nortye
Trial completion, Enrollment change, Trial primary completion date, Metastases: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (clinicaltrials.gov) - Jul 5, 2016 P1, N=17, Completed, Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016 Recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Jul 2016 --> May 2015
- |||||||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Enrollment open, Metastases: INVICTAN (clinicaltrials.gov) - Jun 28, 2016 P3, N=120, Recruiting, N=168 --> 509 Not yet recruiting --> Recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Phase classification, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 28, 2016 P1b/2, N=68, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2
- |||||||||| leucovorin calcium / Generic mfg.
Enrollment open, Phase classification: EFFET: Folinic Acid in Children With Autism Spectrum Disorders (clinicaltrials.gov) - Jun 16, 2016 P2, N=40, Recruiting, Trial primary completion date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting | Phase classification: P4 --> P2
- |||||||||| 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 10, 2016 P2, N=43, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) (clinicaltrials.gov) - Jun 5, 2016 P1, N=180, Completed, Trial primary completion date: Jun 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Aug 2025 --> May 2016
- |||||||||| ipatasertib (RG7440) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 5, 2016 P1, N=118, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Aug 2025 --> May 2016 Trial primary completion date: Nov 2015 --> Feb 2017
|